Home > Insider Trading > Filing (0000902664-24-000903)

Filing Details

Accession Number:: 0000902664-24-000903
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2024-02-01 16:47:58
Reporting Period:: 2024-01-30

Accepted Time:: 2024-02-01 16:47:58
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1868279	Arrivent Biopharma Inc.	AVBP	()	E9

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1510589	Hillhouse Investment Management, Ltd.	Office #122, Windward 3 Building Regatta Office Park, West Bay Road Grand Cayman E9 KY1-9006		No	No	Yes	No
1762304	Hhlr Advisors, Ltd.	Office #122, Windward 3 Building Regatta Office Park, West Bay Road Grand Cayman E9 KY1-9006		No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2024-01-30	3,616,041	$0.00	3,616,041	No	4	C	Indirect	See footnotes
Common Stock	Acquisiton	2024-01-30	313,076	$0.00	3,929,117	No	4	C	Indirect	See footnotes
Common Stock	Acquisiton	2024-01-30	555,555	$18.00	4,484,672	No	4	P	Indirect	See footnotes

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	See footnotes
No	4	C	Indirect	See footnotes
No	4	P	Indirect	See footnotes

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series A Preferred Stock	Disposition	2024-01-30	55,000,000	$0.00	3,616,041	$0.00
Common Stock	Series B Preferred Stock	Disposition	2024-01-30	4,761,903	$0.00	313,076	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0			No	4	C	Indirect
0			No	4	C	Indirect

Footnotes

Immediately prior to the closing of the Issuer's initial public offering, each share of Series A Preferred Stock and Series B Preferred Stock converted into shares of common stock on a 15.21-for-1 basis.
The securities reported herein are held by VSUM VI Holdings Limited ("VSUM VI") and VSUM VIII Holdings Limited ("VSUM VIII"). VSUM VI is a wholly owned subsidiary of Hillhouse Venture Fund V, L.P. ("Hillhouse Venture V") and VSUM VIII is a wholly owned subsidiary of Hillhouse Healthcare Fund, L.P. ("Hillhouse Healthcare"). HIM (as defined below) acts as the sole management company of each of Hillhouse Venture V and Hillhouse Healthcare.
The securities reported herein are held by VSUM VIII and ARVT Holdings Limited ("ARVT"). VSUM VIII is a wholly owned subsidiary of Hillhouse Healthcare and ARVT is a wholly owned subsidiary of Hillhouse Venture Fund VI, L.P. ("Hillhouse Venture VI"). HIM acts as the sole management company of each of Hillhouse Healthcare and Hillhouse Venture VI.
The securities reported herein are held by HHLR Fund, L.P., an exempted Cayman Islands limited partnership ("HHLR Fund"). HHLR (as defined below) acts as the sole management company of HHLR Fund.
This statement is filed by (i) Hillhouse Investment Management, Ltd., an exempted Cayman Islands company ("HIM") and (ii) HHLR Advisors, Ltd., an exempted Cayman Islands company ("HHLR"). The foregoing persons are hereinafter sometimes each referred to as a "Reporting Person" and collectively referred to as the "Reporting Persons." HIM and HHLR are under common control and share certain policies, personnel and resources. Accordingly, HIM and HHLR are filing this Form 4 jointly.
The filing of this statement shall not be deemed an admission that each of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any.